|
|
Volumn 11, Issue 11, 2012, Pages 930-931
|
|
Is the door open again for neuroprotection trials in stroke?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GINSENOSIDE RD;
NA 1;
NEUROPROTECTIVE AGENT;
NORPHENAZONE;
PLACEBO;
POSTSYNAPTIC DENSITY 95 PROTEIN INHIBITOR;
POSTSYNAPTIC DENSITY PROTEIN 95;
TAT NR2B9C;
UNCLASSIFIED DRUG;
AGING;
ANEURYSM RUPTURE;
BLOOD CLOT LYSIS;
BRAIN ARTERY ANEURYSM;
BRAIN INFARCTION;
BRAIN ISCHEMIA;
CEREBROVASCULAR ACCIDENT;
DIFFUSION WEIGHTED IMAGING;
DRUG APPROVAL;
DRUG EFFICACY;
FUNCTIONAL ASSESSMENT;
HEALTH CARE ACCESS;
HUMAN;
LETTER;
NATIONAL INSTITUTES OF HEALTH STROKE SCALE;
NEUROIMAGING;
NEUROPROTECTION;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RANKIN SCALE;
RISK FACTOR;
TREATMENT OUTCOME;
ENDOVASCULAR PROCEDURES;
FEMALE;
HUMANS;
INTRACRANIAL ANEURYSM;
MALE;
PEPTIDES;
STROKE;
|
|
EID: 84867654740
PISSN: 14744422
EISSN: 14744465
Source Type: Journal
DOI: 10.1016/S1474-4422(12)70229-6 Document Type: Letter |
|
Times cited : (11)
|
|
References (5)
|
